遠大醫藥:2023年年報
Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512) rose more than 6% in the intraday period, domestic carbon-14 isotopes, to supply domestic nuclear drugs to the market at the end of the year ushered in new opportunities
Yuanda Pharmaceutical (00512) rose more than 6% in the intraday period. As of press release, it rose 4.94% to HK$4.25, with a turnover of HK$21.15,900.
Hong Kong Stock Concept Tracking | China's first mass production of carbon-14 isotope domestically produced nuclear drugs ushered in new opportunities (with concept stocks)
At 13:48 on April 20, after two years of core irradiation, the first carbon-14 target was successfully removed from the Qinshan Nuclear Power Heavy Water Reactor Unit of China Nuclear Power Investment Holdings under the China Nuclear Power Group. This was the first time that China mass-produced carbon-14 isotopes, solving the problem that domestic carbon-14 isotopes are dependent on imports, and fully localizing carbon-14 supply. Carbon-14 is a radioactive isotope of carbon and is widely used as a tracer. Helicobacter pylori testing is its most representative use. In addition, fields such as pharmacokinetic research and beta-ray environmental monitoring systems also require carbon-14. Previously
Zhitong Hong Kong Shareholders' Rights Disclosure | April 22
Disclosure of Hong Kong Stock Shareholders' Rights | April 22
Yuanda Pharmaceutical (00512.HK) received 95,000 additional shares from Chairman Tang Weikun
Gelonghui, April 22丨According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, Yuanda Pharmaceutical (00512.HK) was granted an increase of 95,000 shares at an average price of HK$3.91 per share on the market, involving approximately HK$371,500. After the increase in holdings, Tang Weikun's latest shareholding was 415,000 shares.
Grand Pharmaceutical Group Limited (HKG:512) Insiders Have Had a Fantastic Week as Stock Increased 6.8%, and They Haven't Stopped Buying
Key Insights Insiders appear to have a vested interest in Grand Pharmaceutical Group's growth, as seen by their sizeable ownership A total of 2 investors have a majority stake in the company with 59
Yuanda Pharmaceutical (00512.HK) was increased by 101,000 shares by Executive Director Zhou Chao
Gelonghui, April 10 | According to the latest equity disclosure data of the Stock Exchange, on April 8, 2024, Yuanda Pharmaceutical (00512.HK) was granted an increase of 101,000 shares by Executive Director Zhou Chao at an average price of HK$3955 per share on the market, involving about HK$39,500. After increasing his holdings, Zhou Chao's latest shareholding was 263,000 shares.
Yuanda Pharmaceutical (00512.HK) introduces innovative global products to treat demodex mite blepharitis and meibomian gland dysfunction caused by demodex
Gelonghui, March 27 | Yuanda Pharmaceutical (00512.HK) announced that the Group reached a strategic cooperation agreement with Liantuo Biotechnology Co., Ltd. and Tarsus Pharmaceuticals, Inc. (“Tarsus”). After the relevant conditions are met, the Group will obtain exclusive rights for the development, production and commercialization of TP-03, a globally innovative ophthalmic formulation for the treatment of demodex blepharitis and meibomian gland dysfunction caused by demodex mite in Greater China at the cost of a down payment of US$15 million and a certain registration milestone fee. this
Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512) rose more than 5%, and a new drug to treat gastrointestinal and pancreatic neuroendocrine tumors was approved for phase III clinical trials
Yuanda Pharmaceutical (00512) rose more than 5% in early trading, and climbed about 15% after the results. As of press release, it rose 5.06% to HK$4.15, with a turnover of HK$8.2581 million.
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug
Grand Pharmaceutical Group (HKG:0512) said China's National Medical Products Administration (NMPA) approved its drug ITM-11 to proceed to Phase III clinical trials, according to a Hong Kong bourse fil
Yuanda Pharmaceutical (00512.HK) was increased by 106,000 shares by Executive Director Zhou Chao
Gelonghui, March 25 | According to the latest equity disclosure data of the Stock Exchange, from March 21 to March 22, 2024, Yuanda Pharmaceutical (00512.HK) obtained executive director Zhou Chao increased his holdings by a total of 106,000 shares at an average price of HK$4.03-4.05 per share on the market, involving approximately HK$428,000. After increasing his holdings, Zhou Chao's latest shareholding was 162,000 shares.
The world's leading nuclear drug company once again spread good news. Yuanda Pharmaceutical (00512) Innovation RDC ITM-11 was approved for Phase III clinical trials in China
The company announced that its globally innovative radionuclide conjugate drug (RDC) ITM-11 for the treatment of gastrointestinal and pancreatic neuroendocrine tumors has recently been approved by the National Drug Administration to conduct phase III clinical research (COMPOSE study).
Yuanda Pharmaceutical (00512.HK) received 100,000 additional shares from Chairman Tang Weikun
Gelonghui, March 22丨According to the latest equity disclosure data of the Stock Exchange, on March 20, 2024, Yuanda Pharmaceutical (00512.HK) was granted an increase of 100,000 shares at an average price of HK$3.8147 per share on the market at an average price of HK$3.8147 per share, involving approximately HK$38.1.47 million. After the increase in holdings, Tang Weikun's latest shareholding was 160,000 shares.
Yuanda Pharmaceutical (00512) will pay a final dividend of HK$0.26 per share on June 27
Yuanda Pharmaceutical (00512) announced that the company will pay a final dividend of 0 per share on June 27, 2024...
Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512) rose more than 5%. Last year's revenue broke HK$10 billion, and the revenue of the core product E-Gantai nearly tripled
Yuanda Pharmaceutical (00512) rose more than 5%. As of press release, it had risen 5.19% to HK$4.05, with a turnover of HK$31.9098 million.
GRANDPHARMA To Go Ex-Dividend On June 6th, 2024 With 0.26 HKD Dividend Per Share
March 20th - $GRANDPHARMA(00512.HK)$ is trading ex-dividend on June 6th, 2024. Shareholders of record on June 7th, 2024 will receive 0.26 HKD dividend per share on June 27th, 2024. The ex-dividend
Yuanda Pharmaceutical (00512) Announces 2023 Annual Results, Innovative R&D, Full Line Promotion of Products to Achieve Echelon Listing
The company recorded annual revenue of approximately HK$10.53 billion, up 15.8% year on year before exchange rate impact; gross profit of about HK$6.52 billion, up 15.3% year on year before exchanging exchange rate effects; net profit attributable to mother of normalization was approximately HK$2.04 billion, up 0.2% year on year before exchanging exchange rate impact.
Yuanda Pharmaceutical (00512.HK): Earnings increased 10.1% year-on-year in 2023 to HK$10.53 billion, with a final interest rate of HK26 cents per share
On March 20, GLONGHUI | Yuanda Pharmaceutical (00512.HK) announced that for the year ended December 31, 2023, the Group's business grew steadily, with revenue of about HK$10.53 billion, an increase of about 10.1% over the previous year. Excluding the effects of changes in the exchange rate between RMB and HKD, this is an increase of about 15.8% compared to the same period in 2022. During the period under review, profit attributable to company owners was approximately HK$1.88 billion, a year-on-year decrease of approximately 9.6%. The current period's normalized profit attributable to company owners was approximately RMB 2,036 million, down about 4.7% from the same period last year. If you leave out the people
GRANDPHARMA: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Hong Kong Stock Concept Tracking | The global nuclear drug market will usher in rapid growth, institutions are optimistic about the acceleration of corporate growth (with concept stocks)
As RLT therapy continues to break through, the overall market growth rate of the nuclear drug racetrack will accelerate.
No Data